Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANR 82
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
ANR 82 is an 8-bromo-9-ethyladenine derivative, classified as a small molecule. It functions as an antagonist of the adenosine A2A receptor. Preclinical studies have demonstrated its ability to reverse haloperidol-induced catalepsy in rat models of Parkinson's disease, suggesting a potential therapeutic role for ameliorating motor deficits associated with the condition.
- Other names
- 8-bromo-9-ethyladenine
Beyond the preview
Go deeper on ANR 82.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANR 82.